Total Payments
$577.38
2024 Payments
$16.29
Companies
13
Transactions
34
Medicare Patients
588
Medicare Billing
$125,776
Payment Breakdown by Category
Food & Beverage$547.39 (94.8%)
Education$29.99 (5.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $547.39 | 33 | 94.8% |
| Education | $29.99 | 1 | 5.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $117.03 | 7 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $111.50 | 7 | $0 (2019) |
| Lundbeck LLC | $75.08 | 4 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $51.16 | 4 | $0 (2018) |
| Vanda Pharmaceuticals Inc. | $40.43 | 2 | $0 (2018) |
| Alkermes, Inc. | $40.11 | 2 | $0 (2019) |
| Indivior Inc. | $30.10 | 2 | $0 (2018) |
| Allergan Inc. | $29.99 | 1 | $0 (2018) |
| Abbott Laboratories | $22.17 | 1 | $0 (2023) |
| Avanir Pharmaceuticals, Inc. | $18.13 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16.29 | 1 | PROTEGA PHARMACEUTIALS INC ($16.29) |
| 2023 | $22.17 | 1 | Abbott Laboratories ($22.17) |
| 2019 | $106.96 | 6 | Lundbeck LLC ($24.73) |
| 2018 | $236.42 | 15 | Janssen Pharmaceuticals, Inc ($57.47) |
| 2017 | $195.54 | 11 | Otsuka America Pharmaceutical, Inc. ($70.18) |
All Payment Transactions
34 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/29/2024 | PROTEGA PHARMACEUTIALS INC | ROXYBOND (Drug) | Food and Beverage | In-kind items and services | $16.29 | General |
| Category: Pain Management | ||||||
| 12/23/2023 | Abbott Laboratories | OCTRODE (Device) | Food and Beverage | In-kind items and services | $22.17 | General |
| Category: Neuromodulation | ||||||
| 06/27/2019 | PFIZER INC. | XTANDI (Drug) | Food and Beverage | In-kind items and services | $13.21 | General |
| Category: ONCOLOGY | ||||||
| 04/08/2019 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $12.18 | General |
| Category: Central Nervous System | ||||||
| 03/26/2019 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $16.21 | General |
| Category: PSYCHIATRY | ||||||
| 03/11/2019 | Lundbeck LLC | BRINTELLIX (Drug) | Food and Beverage | Cash or cash equivalent | $24.73 | General |
| Category: PSYCHIATRY | ||||||
| 02/11/2019 | Janssen Pharmaceuticals, Inc | — | Food and Beverage | In-kind items and services | $17.94 | General |
| 01/22/2019 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: CNS | ||||||
| 11/27/2018 | Indivior Inc. | SUBLOCADE (Drug), SUBOXONE SUBLINGUAL FILM | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: OUD | ||||||
| 10/17/2018 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $10.69 | General |
| Category: CNS | ||||||
| 10/08/2018 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $13.35 | General |
| Category: Neuroscience | ||||||
| 08/28/2018 | Avanir Pharmaceuticals, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 08/13/2018 | Vanda Pharmaceuticals Inc. | Fanapt (Drug), Hetlioz | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: Schizophrenia | ||||||
| 08/01/2018 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: CNS | ||||||
| 06/26/2018 | Janssen Pharmaceuticals, Inc | INVEGA TRINZA (Drug) | Food and Beverage | In-kind items and services | $17.44 | General |
| Category: Neuroscience | ||||||
| 05/15/2018 | Allergan Inc. | VRAYLAR (Drug) | Education | In-kind items and services | $29.99 | General |
| Category: NEUROSCIENCE | ||||||
| 04/24/2018 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $14.43 | General |
| Category: PSYCHIATRY | ||||||
| 04/09/2018 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $15.66 | General |
| Category: PSYCHIATRY | ||||||
| 03/21/2018 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $16.26 | General |
| Category: PSYCHIATRY | ||||||
| 02/27/2018 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $16.21 | General |
| Category: PSYCHIATRY | ||||||
| 02/14/2018 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: Neuroscience | ||||||
| 01/26/2018 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $7.86 | General |
| Category: CNS | ||||||
| 01/23/2018 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug), INVEGA TRINZA | Food and Beverage | In-kind items and services | $13.35 | General |
| Category: Neuroscience | ||||||
| 10/24/2017 | Indivior Inc. | SUBOXONE SUBLINGUAL FILM (Drug) | Food and Beverage | Cash or cash equivalent | $13.46 | General |
| Category: OUD | ||||||
| 10/09/2017 | Janssen Pharmaceuticals, Inc | INVEGA TRINZA (Drug) | Food and Beverage | In-kind items and services | $22.52 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 124 | 514 | $61,043 | $34,082 |
| 2022 | 4 | 160 | 504 | $61,336 | $30,111 |
| 2021 | 4 | 172 | 527 | $63,887 | $33,155 |
| 2020 | 4 | 132 | 457 | $52,041 | $28,427 |
Total Patients
588
Total Services
2,002
Medicare Billing
$125,776
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 52 | 435 | $45,675 | $26,193 | 57.3% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2023 | 28 | 30 | $6,930 | $3,934 | 56.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 31 | 34 | $6,188 | $2,843 | 45.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 15 | $2,250 | $1,112 | 49.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 71 | 394 | $41,370 | $20,897 | 50.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 42 | 52 | $7,800 | $3,731 | 47.8% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 36 | 44 | $8,008 | $3,479 | 43.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 14 | $4,158 | $2,004 | 48.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 70 | 412 | $43,260 | $23,160 | 53.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 50 | 55 | $10,010 | $4,535 | 45.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 41 | 49 | $7,350 | $3,832 | 52.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 11 | 11 | $3,267 | $1,628 | 49.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 52 | 361 | $37,905 | $20,953 | 55.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 37 | 43 | $6,450 | $3,561 | 55.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 24 | 25 | $4,550 | $2,140 | 47.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 19 | 28 | $3,136 | $1,773 | 56.5% |
About Dr. John Rice, M.D
Dr. John Rice, M.D is a Counselor healthcare provider based in Brevard, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/16/2005. The National Provider Identifier (NPI) number assigned to this provider is 1134105612.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Rice, M.D has received a total of $577.38 in payments from pharmaceutical and medical device companies, with $16.29 received in 2024. These payments were reported across 34 transactions from 13 companies. The most common payment nature is "Food and Beverage" ($547.39).
As a Medicare-enrolled provider, Rice has provided services to 588 Medicare beneficiaries, totaling 2,002 services with total Medicare billing of $125,776. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Counselor
- Other Specialties Psychiatry
- Location Brevard, NC
- Active Since 12/16/2005
- Last Updated 02/06/2026
- Taxonomy Code 101Y00000X
- Entity Type Individual
- NPI Number 1134105612
Products in Payments
- ABILIFY MAINTENA (Drug) $86.24
- REXULTI (Drug) $81.14
- INVEGA TRINZA (Drug) $53.53
- LATUDA (Drug) $51.16
- Fanapt (Drug) $40.43
- INVEGA SUSTENNA (Drug) $40.03
- VRAYLAR (Drug) $29.99
- BRINTELLIX (Drug) $24.73
- ARISTADA (Drug) $22.69
- OCTRODE (Device) $22.17
- NUEDEXTA (Drug) $18.13
- Aristada 441 mg (Drug) $17.42
- SUBLOCADE (Drug) $16.64
- ROXYBOND (Drug) $16.29
- SUBOXONE SUBLINGUAL FILM (Drug) $13.46
- XTANDI (Drug) $13.21
- AUSTEDO (Drug) $12.18
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.